Amsbio Pre-packaged cDNA ORG and miRNA Adenoviruses

Dec 18, 2015

Amsbio has launched a collection of pre-packaged human full-length cDNA ORG and miRNA adenoviruses. The collection features over 1,240 pre-packaged human miRNA precursor adenoviruses and 30,000 pre-packaged human full length cDNA ORG adenoviruses. The pre-packaged recombinant adenovirus will demonstrate observable gene expression in less than 24 hours, the company said. All pre-packaged adenoviruses have been validated by western blot in HEK293 cells. The collection will considerably enhance the high throughput drug discovery, improve functional genomic studies, and make life science research more cost-effective and efficient, the company said. 

More Like This

Sep 19, 2017

Explify Respiratory

ARUP Laboratories and IDbyDNA, a data analytics-driven metagenomics company, launched Explify Respiratory, a next-generation sequencing-based test for respiratory infections. Explify Respiratory detects more than 200 common and rare bacterial, fungal, and viral respiratory pathogens with a single test. It is powered by IDbyDNA's Taxonomer software, a DNA search engine that can rapidly identify any organism by its genetic material. The test is the first in a line of tests that the two companies plan to launch as part of a previously announced strategic partnership to develop and commercialize infectious disease testing using metagenomics.

Sep 18, 2017

Horizon Discovery CRISPRi and CRISPRa Screening Services

Horizon Discovery announced that it has expanded its functional genomic screening portfolio to include CRISPRi (interference) and CRISPRa (activation) screening services. Horizon's CRISPRi/CRISPRa screening platform substantially broadens the range of possible studies through the capacity to reduce or increase, rather than completely eliminating gene expression, the company said. This enables customers to address critical gaps in target ID and validation as they work to develop novel and more effective drug therapies. The screening capabilities are based on the company's highly optimised CRISPR knockout screening platform. Horizon has also developed an enhanced solution that combines both CRISPRi and CRISPRa screening. This combined solution can reveal 'switch' like genes that display opposing effects when activated or inhibited in the presence of the drug of interest.

Sep 18, 2017

Evosep One

Evosep introduced Evosep One, an optimized separation technology for mass spectrometers for large cohort experiments. Evosep One is designed for fast and robust separation of omics samples while enabling 24 hour operation at 200 samples a day. The product reduces cross-contamination through the use of disposable tips, and high flow rate during autosampler washing steps. According to the company, Evosep One also improves up-time and reliability through partial elution that leaves impurities from each sample on the disposable tips that act as pre-columns, and from low-pressure elution and gradient formation that causes less wear and tear.

Sep 14, 2017

Qnostics ME Evaluation Panel

Qnostics launched the ME Evaluation Panel for meningitis/encephalitis evaluation. It consists of 14 controls for the qualitative detection of bacterial, viral, and fungal targets, including Neisseria meningitidis, Haemophilus influenzae, Escherichia coli K1, and others. The panel can be used to independently monitor each target and all phases of the testing process, Qnostics said, adding it was designed with known performance on the BioFire FilmArray platform. 

Sep 13, 2017

Phosphorous Ophthalmology, Drug Response Test

Computational genomics firm Phosphorus launched a test for inherited conditions associated with vision loss and blindness, and a pharmacogenomic test to assess the efficacy of various drugs based on their genetic makeup. The ophthalmology genetic test covers retinal disorders, cataracts, glaucoma, and corneal dystrophy. The drug response test covers cardiology, psychiatry, oncology, pain management, neurology, immunology. gastroenterology, repiratory, infectious disease, and others. 

Sep 13, 2017

BC Platforms BC|RQUEST

BC Platforms has introduced BC|RQUEST, a system for analyzing and viewing aggregated genomic and clinical data from multiple biobanks. The platform will be available to members of the Open Biobank Research Enhancement Alliance (OBREA), which Basel, Switzerland-based BC Platforms created.

Sep 13, 2017

Variantyx Unity

Variantyx launched the Variantyx Unity test, a genomic diagnostic test that identifies small sequence changes, structural variants, trinucleotide repeat expansions, and mitochondrial variants from a single DNA sample. The test uses whole-genome seuqncing data analyzed by the firm's Genomic Intelligence platform, and eliminates the need for multiple sequential tests, the firm said. 

Sep 12, 2017

DiaSorin Molecular Simplexa C. difficile Direct Assay

DiaSorin Molecular has launched the Simplexa C. difficile Direct Assay in the US. The assay aids in the diagnosis of infection by detecting the C. difficile toxin B gene in liquid or unformed stool samples, and had been available outside the US since November. The US Food and Drug Administration cleared the test in February

Sep 12, 2017

Benson Hill Biosystems CRISPR 3.0

Benson Hill Biosystems has launched CRISPR 3.0, a novel family of Cms1 nucleases, as part of its suite of genomics tools to accelerate crop performance improvements. The CRISPR 3.0 portfolio of nucleases demonstrate a shorter length than many other widely-used nucleases, enabling easier delivery, the firm said.

Sep 12, 2017

Bio-Rad ZDC Multiplex RT-PCR assay

Bio-Rad Laboratories has launched the ZDC Multiplex RT-PCR assay, a research-use only tool for the simultaneous screening of sample for Zika, dengue, and chikungunya arbovirus RNAs. The assay comes with all controls that researchers need to validate results internally. The RT-PCR kit was launched outside the US earlier this year. 

Sep 12, 2017

Becton Dickinson Rhapsody Platform Assay

Becton Dickinson announced the launch of BD Rhapsody, a platform for single cell RNA analysis. According to BD, the system consists of reagents, instruments, and software for targeted gene expression analysis of ten of thousands of individual cells. The platform will also expand beyond RNA expression to include protein detection. BD will offer both application-specific targeted panels and enable customers to design their own custom, targeted panels.

Sep 11, 2017

Tecan Resolvex for LC-MS Sample Prep

Tecan has launched the automated Resolvex A200 positive pressure workstation for LC-MS sample prep. The platform offers unattended positive pressure solid phase extraction, providing increased walkaway times for LC-MS sample preparation workflows. Eight-channel dispensing delivers a three-fold increase in speed compared to single-channel dispensing, and the touchscreen control enables straightforward integration into laboratory protocols. The system is compatible with Tecan's range of 96-well plate and column format smart consumables, including narrow bore extraction columns that transform an extraction column into a reaction vessel.

Sep 07, 2017

Eurofins Genoma GeneSafe

Eurofins Genoma has introduced GeneSafe, a non-invasive prenatal test that screens for both de novo and inherited single-gene disorders. Current commercial NIPTs only screen for aneuploidies and microdeletions, the firm said. GeneSafe identifies fetal conditions that could be missed by traditional prenatal testing, detecting more than 40 severe genetic disorders that may occur in the absence of a family history of the condition. The company said it also detects disorders with an increased prevalence associated with advanced paternal age. The test requires a small blood sample and has a turnaround time of 10 days. It works as a complementary screen to traditional NIPT, providing a more complete picture of the risk of a pregnancy being affected by a genetic disorder, the company noted.

Sep 07, 2017

Myriad Genetics riskScore

Myriad Genetics has launched riskScore, which employs a proprietary algorithm combining analysis of 80 SNPs and patients' personal and family history of cancer to determine a woman's risk of breast cancer. Results from this test will be reported alongside Myriad's myRisk Hereditary Cancer test, a 28-gene panel that gauges patients' risk for for eight cancers. RiskScore will help guide decisions for asymptomatic patients who get negative myRisk results, providing definitive answers to the 90 percent of patients testing negative for hereditary cancer genes, the company noted. Myriad has completed two validation studies in patients of European descent that it will present at upcoming conferences.

Sep 07, 2017

Ranomics VariantFind DNA Library Synthesis

Ranomics, a Toronto-based biotechnology firm, has launched VariantFind, a proprietary platform for creating DNA libraries. VariantFind uses multiplexing technology to incorporate a large number of mutagenic oligonucleotides into a single series of PCR reactions to create high-quality and cost-effective variant libraries for use in protein engineering, synthetic biology, and agriculture, the company said. The resulting libraries can be easily integrated into different workflows, Ranomics added.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.